Shigeyuki Takada

This inventor holds 16 USPTO granted patents. Top assignees: Takeda Chemical Industries, Inc., Takeda Pharmaceutical Company Limited. Active years: 1986-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shigeyuki Takada. Retrieved from https://idiyas.com/inventor/shigeyuki-takada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16

% Patents Active = 81.3

Average Co-Inventor Count = 3.0

ph-index = 11

Forward Citations = 816(Granted Patents)

Location History:

Suita, JP (1990)
Osaka, JP (1986 - 1996)
Salt Lake City, UT (US) (1997)
Kobe, JP (2000 - 2001)
Hyogo, JP (1999 - 2002)
Nishimoniya, JP (2004)
Nishinomiya, JP (2004 - 2014)

Company Filing History:

14 out of 1,858

Takeda Chemical Industries, Inc.

patents

2 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 1986-2014

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8637077 - Sustained-release preparation (2014-01-28),

2. 7090869 - Method for producing preparation containing bioactive substance (2006-08-15),

3. 6723347 - Proces for producing protein powder (2004-04-20),

4. 6706732 - Nasal preparation of guanidinoimino quinoline derivatives (2004-03-16),

5. 6419961 - Sustained release microcapsules of a bioactive substance and a biodegradable polymer (2002-07-16),

6. 6190702 - Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase (2001-02-20),

7. 6117455 - Sustained-release microcapsule of amorphous water-soluble pharmaceutical (2000-09-12),

8. 6113941 - Substained release microcapsule of physiologically active compound which (2000-09-05),

9. 6045830 - Method of production of sustained-release preparation (2000-04-04),

10. 5876756 - Microcapsule containing amorphous water-soluble 2-piperazinone-1-acetic (1999-03-02),

11. 5651990 - Prolonged release microparticle preparation and production of the same (1997-07-29),

12. 5622657 - Prolonged release microparticle preparation and production of the same (1997-04-22),

13. 5554378 - Pharmaceutical composition and its mucosal use (1996-09-10),

14. 5330767 - Sustained release microcapsule (1994-07-19),

15. 4954298 - Method for producing microcapsule (1990-09-04),

Title: Shigeyuki Takada: Innovator in Sustained-Release Preparations

Introduction

Shigeyuki Takada is a prominent inventor based in Nishinomiya, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of sustained-release preparations. With a total of 16 patents to his name, Takada's work has had a lasting impact on drug delivery systems.

Latest Patents

Among his latest patents, Takada has developed a sustained-release preparation that suppresses the initial release of a physiologically active substance. This innovative preparation allows for a constant release of the active substance over an extended period. Additionally, he has created a method for producing a preparation containing a bioactive substance, which involves forming a solid material with a polymer and treating it with high-pressure gas. This method minimizes the excessive initial release of the bioactive substance and reduces deterioration and residual organic solvents.

Career Highlights

Takada has worked with notable companies in the pharmaceutical industry, including Takeda Chemical Industries, Inc. and Takeda Pharmaceutical Company Limited. His experience in these organizations has contributed to his expertise in drug formulation and delivery systems.

Collaborations

Throughout his career, Takada has collaborated with esteemed colleagues such as Susumu Iwasa and Yasuaki Ogawa. These partnerships have fostered innovation and advancement in the field of pharmaceuticals.

Conclusion

Shigeyuki Takada's contributions to sustained-release preparations and bioactive substance formulations highlight his role as a leading inventor in the pharmaceutical industry. His work continues to influence drug delivery systems and improve patient outcomes.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]